Cambridge-based Anthos Therapeutics and its parent company, private investment platform Blackstone Life Sciences, have entered into an agreement with Novartis to acquire Anthos for up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor […]

In a sign of a biotech rebound, Massachusetts-headquartered biopharma companies received $7.89 billion in venture capital (VC) funding, marking the first year-over-year increase since the pandemic, according to a newly released year-end report from biopharma member organization MassBio. For the first time ever, the report also found that private biopharma companies based in Boston collected more venture […]

Eli Lilly has agreed to acquire Scorpion’s PI3Kα inhibitor STX-478 which is currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. STX-478 could represent the next generation of PI3Kα targeting agents by selectively targeting the pathway in cancerous but not healthy cells, thus overcoming a key limitation […]

IDRx, a Boston-based, clinical-stage biopharm dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST) is being acquired by GSK. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule IDRX-42 being developed as a first- […]

Cambridge-based gene editing company Editas Medicine is planning a critical pivot to optimize its cost structure, extend its cash runway into Q2 2027, and position the company to accelerate its intent to achieve in vivo human proof of concept in approximately two years. “Recent scientific breakthroughs by the Editas team have convinced us that the timelines around […]

Watertown-based Neumora Therapeutics, a clinical-stage biopharm with a pipeline consisting of seven clinical and pre-clinical brain disease programs, has announced disappointing results from a Phase 3 study of navacaprant for the treatment of major depressive disorder (MDD). The study did not demonstrate a statistically significant improvement in MDD study participants overall. “We are disappointed by […]

Sarepta Therapeutics has inked an exclusive licensing and collaboration agreement with Arrowhead Pharmaceuticals under which Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and lungs. The agreement will add meaningfully to Sarepta’s mid- and early-stage pipeline, complementing the Company’s existing leadership in […]

The diversity of life testifies to proteins’ amazing capacity as chemical tools. They control and drive all the chemi­cal reactions that together are the basis of life. Proteins also function as hormones, signal substances, antibodies and the building blocks of different tissues. This year’s Nobel Prize in Chemistry is shared by three scientists who have […]

Gary Ruvkun, professor of genetics at Harvard Medical School and an investigator at Massachusetts General Hospital, and Victor Ambros, of the University of Massachusetts Chan Medical School. have received the 2024 Nobel Prize in Medicine for the discovery of microRNAs, a class of tiny RNA molecules that regulate the activities of genes in plants and animals, including […]

In the largest lease deal for newly-built lab space so far this year, The Davis Companies and Boston Development Group (BDG) have entered into lease agreements with life sciences firms LifeMine Therapeutics and a new stealth-mode biotech (NewCo) for space in the brand-new, purpose-built, 225K square-foot, Class A life science building at 66 Galen Street […]